Back to News
M&A

Behind the Buyouts: Goldman's Dubner on Rise in Spinoffs

|
Published: December 19th, 2023
Goldman Sachs global head of M&A structuring David Dubner discusses the growth in corporate separations, particularly at large-cap businesses with diversified operations, amid a rise in interest rates over the past couple of years.

On the latest episode of The Deal’s Behind the Buyouts podcast, Goldman, Sachs & Co.’s global head of M&A structuring, David Dubner, dives into the rise in spinoffs and divestitures globally.

The number of such transactions, or “corporate separations” as Dubner calls them, reached their highest in a decade at 30 global deals in 2022, according to a May report from Goldman and Ernst & Young LLP.

“A profound change we have seen in the capital markets over the past few years has been the rise in interest rates, rising cost of capital, and what that’s led to is corporate boards and management teams reassessing effectively what they are the optimal owners of,” Dubner said.

While spinoffs tend to be size and industry agnostic, Dubner said a growing number of transactions have been above $5 billion, with industrials and healthcare — which tend to have more complex portfolios — accounting for 50% of globally announced transactions in 2022.

Goldman has advised on major spinoffs such as Kellogg Co.’s split into two publicly traded companies, Kellanova (K) and WK Kellogg Co. (KLG) in October, and Johnson & Johnson’s (JNJ) separation of its consumer health business, Kenvue Inc. (KVUE), in May.

Listen to the full podcast with David Dubner below:

More podcasts from The Deal are available on iTunes, Spotify and on TheDeal.com. 

More From M&A

M&A

Deal Diary: Cleary, Paul Weiss on CPP Sale to GE Aerospace

By David Marcus
|
Published: September 16th, 2026
Warburg Pincus and Berkshire Partners portfolio company CPP taps Cleary on an $11.75 billion agreement to sell to GE Aerospace, which uses Paul Weiss. The Deal in July reported CPP was exploring strategic options.
M&A

Deal Diary: Centerview, Legal Trio Work Precision Medicine Sale

By David Marcus
|
Published: August 25th, 2026
Blackstone holding Precision Medicine taps Centerview and Simpson Thacher on a $2.25 billion agreement to sell to McKesson, which uses Davis Polk. The Deal reported in January that Blackstone had tapped Centerview to run an auction.